Baxter International Inc. (NYSE: BAX) announced today that it has ceased production of its first batch of commercial CELVAPAN pandemic H1N1 vaccine in late July and is studying plans for distribution in accordance with national health authorities to obtain necessary clearances rating. CELVAPAN, brand name of the company's H1N1 pandemic flu vaccine, uses a patented Baxter, Vero cell culture technology.
Baxter intends to submit the initial quantities CELVAPAN state public health pandemic enterprise agreements. They subscribe to the vaccine after health (World Health Organization lift), 6th level, you know phase and the declaration of a pandemic.
Baxter Real Estate, Vero cell technology in the production of the expectations of the company quickly produced in response to a pandemic vaccine. CELVAPAN was developed and produced in this process within 12 weeks of receipt of H1N1 virus, which represents a breakthrough in vaccine production.
"We are very pleased with our company's ability to meet their waiting time for the development and production of CELVAPAN," said Joy Amundson, Corporate Vice President and President of Baxter Bioscience. "This is an encouraging validation of our science, our technology team, and Vero cell vaccine, Baxter, fulfilling this important goal to help solve the pressing problem of public health."
Baxter intends to submit the initial quantities CELVAPAN state public health pandemic enterprise agreements. They subscribe to the vaccine after health (World Health Organization lift), 6th level, you know phase and the declaration of a pandemic.
Baxter Real Estate, Vero cell technology in the production of the expectations of the company quickly produced in response to a pandemic vaccine. CELVAPAN was developed and produced in this process within 12 weeks of receipt of H1N1 virus, which represents a breakthrough in vaccine production.
"We are very pleased with our company's ability to meet their waiting time for the development and production of CELVAPAN," said Joy Amundson, Corporate Vice President and President of Baxter Bioscience. "This is an encouraging validation of our science, our technology team, and Vero cell vaccine, Baxter, fulfilling this important goal to help solve the pressing problem of public health."
No comments:
Post a Comment